The EDGE

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside

V Boisguérin, J C Castle, M Loewer, J Diekmann, F Mueller, C M Britten, S Kreiter, Ö Türeci and U Sahin

Br J Cancer 2014 111: 1469-1475; 10.1038/bjc.2013.820

Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective

J T Lear, C Corner, P Dziewulski, K Fife, G L Ross, S Varma and C A Harwood

Br J Cancer 2014 111: 1476-1481; advance online publication, September 11, 2014; 10.1038/bjc.2014.270

Clinical Studies

Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer

T B Hao, W Shi, X J Shen, J Qi, X H Wu, Y Wu, Y Y Tang and S Q Ju

Br J Cancer 2014 111: 1482-1489; advance online publication, August 26, 2014; 10.1038/bjc.2014.470

Comparing primary and secondary health-care use between diagnostic routes before a colorectal cancer diagnosis: Cohort study using linked data

J R Sheringham, T Georghiou, X A Chitnis and M Bardsley

Br J Cancer 2014 111: 1490-1499; advance online publication, July 29, 2014; 10.1038/bjc.2014.424

Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone

R Mirnezami, A M Mehta, K Chandrakumaran, T Cecil, B J Moran, N Carr, V J Verwaal, F Mohamed and A H Mirnezami

Br J Cancer 2014 111: 1500-1508; advance online publication, September 16, 2014; 10.1038/bjc.2014.419

Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences

P Balermpas, F Rödel, R Liberz, J Oppermann, J Wagenblast, S Ghanaati, P N Harter, M Mittelbronn, C Weiss, C Rödel and E Fokas

Br J Cancer 2014 111: 1509-1518; advance online publication, August 5, 2014; 10.1038/bjc.2014.446

Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study

J Sehouli, A Reinthaller, C Marth, D Reimer, T Reimer, W Stummvoll, L Angleitner-Boubenizek, B Brandt and R Chekerov

Br J Cancer 2014 111: 1519-1525; advance online publication, September 16, 2014; 10.1038/bjc.2014.443

Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma

S L Hofbauer, K I Stangl, M de Martino, I Lucca, A Haitel, S F Shariat and T Klatte

Br J Cancer 2014 111: 1526-1531; advance online publication, August 12, 2014; 10.1038/bjc.2014.450

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

A Prat, A Lluch, J Albanell, W T Barry, C Fan, J I Chacón, J S Parker, L Calvo, A Plazaola, A Arcusa, M A Seguí-Palmer, O Burgues, N Ribelles, A Rodriguez-Lescure, A Guerrero, M Ruiz-Borrego, B Munarriz, J A López, B Adamo, M C U Cheang, Y Li, Z Hu, M L Gulley, M J Vidal, B N Pitcher, M C Liu, M L Citron, M J Ellis, E Mardis, T Vickery, C A Hudis, E P Winer, L A Carey, R Caballero, E Carrasco, M Martín, C M Perou and E Alba

Br J Cancer 2014 111: 1532-1541; advance online publication, August 7, 2014; 10.1038/bjc.2014.444

Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk

C H Ahern, Y-C T Shih, W Dong, G Parmigiani and Y Shen

Br J Cancer 2014 111: 1542-1551; advance online publication, August 19, 2014; 10.1038/bjc.2014.458

Translational Therapeutics

Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway

H Ghebeh, S Al-Khaldi, S Olabi, A Al-Dhfyan, F Al-Mohanna, R Barnawi, A Tulbah, T Al-Tweigeri, D Ajarim and M Al-Alwan

Br J Cancer 2014 111: 1552-1561; advance online publication, August 12, 2014; 10.1038/bjc.2014.453

In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells

P Jiang, R Mukthavaram, Y Chao, N Nomura, I S Bharati, V Fogal, S Pastorino, D Teng, X Cong, S C Pingle, S Kapoor, K Shetty, A Aggrawal, S Vali, T Abbasi, S Chien and S Kesari

Br J Cancer 2014 111: 1562-1571; advance online publication, August 5, 2014; 10.1038/bjc.2014.431

MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer

S Hasegawa, H Eguchi, H Nagano, M Konno, Y Tomimaru, H Wada, N Hama, K Kawamoto, S Kobayashi, N Nishida, J Koseki, T Nishimura, N Gotoh, S Ohno, N Yabuta, H Nojima, M Mori, Y Doki and H Ishii

Br J Cancer 2014 111: 1572-1580; advance online publication, August 12, 2014; 10.1038/bjc.2014.454

Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance

S K Ganapathi, A D Beggs, S V Hodgson and D Kumar

Br J Cancer 2014 111: 1581-1589; advance online publication, September 16, 2014; 10.1038/bjc.2014.477

Molecular Diagnostics

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib

A J C Pommier, R Shaw, S K M Spencer, S R Morgan, P M Hoff, J D Robertson, S T Barry and J M Jürgensmeier

Br J Cancer 2014 111: 1590-1604; advance online publication, August 14, 2014; 10.1038/bjc.2014.436

Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers

T Kantola, J P Väyrynen, K Klintrup, J Mäkelä, S M Karppinen, T Pihlajaniemi, H Autio-Harmainen, T J Karttunen, M J Mäkinen and A Tuomisto

Br J Cancer 2014 111: 1605-1613; advance online publication, August 19, 2014; 10.1038/bjc.2014.456

Plasma microRNA profiles: identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma

S Komatsu, D Ichikawa, S Hirajima, T Kawaguchi, M Miyamae, W Okajima, T Ohashi, T Arita, H Konishi, A Shiozaki, H Fujiwara, K Okamoto, N Yagi and E Otsuji

Br J Cancer 2014 111: 1614-1624; advance online publication, August 12, 2014; 10.1038/bjc.2014.451

BRAF^V600E melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity

C A Whipple and C E Brinckerhoff

Br J Cancer 2014 111: 1625-1633; advance online publication, August 12, 2014; 10.1038/bjc.2014.452

The glycosphingolipid P₁ is an ovarian cancer-associated carbohydrate antigen involved in migration

F Jacob, M Anugraham, T Pochechueva, B W C Tse, S Alam, R Guertler, N V Bovin, A Fedier, N F Hacker, M E Huflejt, N Packer and V A Heinzelmann-Schwarz

Br J Cancer 2014 111: 1634-1645; advance online publication, August 28, 2014; 10.1038/bjc.2014.455

Phorbol ester stimulates ethanolamine release from the metastatic basal prostate cancer cell line PC3 but not from prostate epithelial cell lines LNCaP and P4E6

J Schmitt, A Noble, M Otsuka, P Berry, N J Maitland and M G Rumsby

Br J Cancer 2014 111: 1646-1656; advance online publication, August 19, 2014; 10.1038/bjc.2014.457

Genetics and Genomics

Identification of 33 candidate oncogenes by screening for base-specific mutations

S Tuupanen, U A Hänninen, J Kondelin, P von Nandelstadh, T Cajuso, A E Gylfe, R Katainen, T Tanskanen, H Ristolainen, J Böhm, J-P Mecklin, H Järvinen, L Renkonen-Sinisalo, C L Andersen, M Taipale, J Taipale, P Vahteristo, K Lehti, E Pitkänen and L A Aaltonen

Br J Cancer 2014 111: 1657-1662; advance online publication, August 12, 2014; 10.1038/bjc.2014.429

Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role

P-L Clermont, L Sun, F Crea, K L Thu, A Zhang, A Parolia, W L Lam and C D Helgason

Br J Cancer 2014 111: 1663-1672; advance online publication, September 16, 2014; 10.1038/bjc.2014.474

Letters to the Editor

Comment on ‘Strong reduction of AGO2 expression in melanoma and cellular consequences’

M Sand, D Georgas, S Hessam and F G Bechara

Br J Cancer 2014 111: 1673; advance online publication, February 20, 2014; 10.1038/bjc.2014.56

Reply to comment on: strong reduction of AGO2 expression in melanoma and cellular consequences

D Völler and A Bosserhoff

Br J Cancer 2014 111: 1673; advance online publication, February 20, 2014; 10.1038/bjc.2014.57

Comment on ‘The latency period of mesothelioma among a cohort of British asbestos workers (1978–2005)’: methodological problems with case-only survival analysis

D Consonni, F Barone-Adesi and C Mensi

Br J Cancer 2014 111: 1674; advance online publication, April 29, 2014; 10.1038/bjc.2013.823

Comment on ‘The latency period of mesothelioma among a cohort of British asbestos workers (1978–2005)’

D Mirabelli and D Zugna

Br J Cancer 2014 111: 1675; advance online publication, February 27, 2014; 10.1038/bjc.2014.111

Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult

S Boeck, M Haas, S Ormanns, S Kruger, J T Siveke and V Heinemann

Br J Cancer 2014 111: 1675-1676; advance online publication, March 18, 2014; 10.1038/bjc.2014.60

Stellate cells, a point of light in the dark night of pancreatic cancer

N Ramírez, A Viúdez, I Hernández-García, D Guerrero, M Gómez-Dorronsoro, F J Herrera, J Vila, L Beloki, M Ciaúrriz, C Mansilla and R Vera

Br J Cancer 2014 111: 1676-1677; advance online publication, March 18, 2014; 10.1038/bjc.2014.59

Reply: ‘Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer’

R Alvarez, M Musteanu, E Garcia-Garcia, P P Lopez-Casas, D Megias, C Guerra, M Muñoz, Y Quijano, A Cubillo, J Rodriguez-Pascual, C Plaza, E de Vicente, S Prados, S Tabernero, M Barbacid, F Lopez-Rios and M Hidalgo

Br J Cancer 2014 111: 1677-1678; advance online publication, March 18, 2014; 10.1038/bjc.2014.129

Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

A M Menzies, J S Wilmott, G V Long and R A Scolyer

Br J Cancer 2014 111: 1678-1679; advance online publication, December 24, 2013; 10.1038/bjc.2013.796

Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

L Heinzerling, G Schuler, A Hartmann and R Schneider-Stock

Br J Cancer 2014 111: 1679-1680; advance online publication, May 15, 2014; 10.1038/bjc.2014.247